Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

ECOCAPTURE@HOME: assessing apathy and its consequences in everyday life

Published on: 23/09/2021 Reading time: 1 min
apathie
Retour à la recherche

Apathy, a pathological absence of motivation and emotion, is a common symptom of many neurological and psychiatric diseases, such as dementia or depression. The ECOCAPTURE@HOME program, developed by researchers and clinicians at the Paris Brain Institute, aims to establish a precise diagnosis of apathy and to set up personalised care for patients.

Titre à supprimer

Apathy is the most common neuropsychiatric symptom in neurodegenerative diseases such as Alzheimer's, Parkinson's or fronto-temporal degeneration. It is associated with greater cognitive impairment and an overall deterioration in the quality of life of patients and their carers. Indeed, this pathological loss of motivation makes daily activities a real challenge.

Drug treatments for apathy, mainly antidepressants, show only moderate effects. Non-medicinal approaches such as psychotherapy require a very precise assessment of the degree of apathy in each patient in order to propose personalised treatment and hope for an improvement in symptoms.

Define and assess apathy is far from obvious. Apathy can take many different forms and clinical assessment scales are biased by the subjectivity of the evaluator, usually the patient themselves or their carer

Valérie Godefroy first author of the study and post-doctoral fellow under the supervision of Bénédicte Batrancourt (Inserm)

The ECOCAPTURE programme, led at the Paris Brain Institute by Bénédicte Batrancourt (Inserm) and Richard Lévy (AP-HP/Sorbonne University), aims to develop new approaches to measuring apathy. It has recently defined several forms of the behavioural variant of frontotemporal dementia (FTD), through evaluation in the functional exploration room of the PRISME core facility.

In order to be as close as possible to the real-life conditions of patients, one of the objectives of ECOCAPTURE is to bring its assessment tools directly to their homes. This study, ECOCAPTURE@HOME, has been set up to validate a method for monitoring apathy at a distance. To do this, the researchers and clinicians at the Brain Institute wish to recruit 40 patient-caregiver pairs, 20 for Alzheimer's disease, 20 for the behavioural variant of FTD, and 20 control subjects without pathology. The data will be acquired using a connected watch and questionnaires on a smartphone application.

Our objective is to validate the relevance of our measurement method based on three behavioural markers of apathy: daytime activity, sleep quality and the emergence of emotions. If the results are positive, ECOCAPTURE@HOME could enable a better diagnosis of apathy in order to implement personalised management in the daily lives of patients

Bénédicte Batrancourt the study's last author

The Paris Brain Institute thanks the Malakoff Humanis group for its support of the Ecocapture project.

Sources

https://pubmed.ncbi.nlm.nih.gov/34360133/
ECOCAPTURE@HOME: Protocol for the Remote Assessment of Apathy and Its Everyday-Life Consequences. Godefroy V, Levy R, Bouzigues A, Rametti-Lacroux A, Migliaccio R, Batrancourt B. Int J Environ Res Public Health. 2021 Jul 2

Our news on the subject

Stimuler les mitochondries pour doper la mémoire à long terme
Stimulating Mitochondria to Boost Long-Term Memory
An international team led by Jaime de Juan-Sanz at the Paris Brain Institute has shown that slightly increasing the metabolic capacity of neurons can enhance long-term memory in both fruit flies and mice. The study, published in Nature Metabolism...
02.24.2026 Research, science & health
Traitements anti-Alzheimer
Anti-Alzheimer Treatments: A Long-Term Beneficial Effect on Symptoms
There is currently no cure for Alzheimer's disease. The treatments available in France—which are not reimbursed—are known as symptomatic treatments, meaning that they act on the consequences of the disease rather than its underlying cause. In 2018...
02.19.2026 Research, science & health
État de mal épileptique
Status Epilepticus: New Insights Gained from National Health Data
The most severe form of epilepsy, status epilepticus is a high-risk neurological emergency. Yet its epidemiology remains poorly understood, particularly in France. By analyzing data from the French National Health Insurance system, compiled within...
02.19.2026 Research, science & health
Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
See all our news